Fiorucci Stefano, Distrutti Eleonora, Mencarelli Andrea, Morelli Antonio, Laufor Stefan A, Cirino Giuseppe, Wallace John L
Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Perugia, Perugia, Italy.
Br J Pharmacol. 2003 Aug;139(7):1351-9. doi: 10.1038/sj.bjp.0705356.
(1) Unlike other nonsteroidal anti-inflammatory drugs that inhibit formation of cyclooxygenase (COX)-dependent eicosanoids, acetylation of COX-2 by aspirin switches eicosanoid biosynthesis from prostaglandin E(2) (PGE(2)) to 15-epi-lipoxin A(4) (15-epi-LXA(4) or aspirin-triggered lipoxin, ATL). ATL formation by activated leukocytes (PMN) requires the intervention of 5-lipoxygenase (5-LOX), an enzyme that is involved in leukotriene B(4) (LTB(4)) formation. (2) In the present study, we have examined the role of acetylated COX-2 and 5-LOX in modulating antiadhesive effects of aspirin on adhesion of PMN to endotoxin (LPS)-primed human umbilical endothelial cells (HUVEC). (3) Treating PMN/HUVEC cocultures with aspirin resulted in a concentration-dependent inhibition of cell-to-cell adhesion induced by LPS. Treating HUVEC with selective COX-2 inhibitors, celecoxib and rofecoxib, caused an approximately 70% reversion of antiadhesive effect of aspirin. In contrast, inhibition of neutrophil's 5-LOX pathway with 1 micro M ZD2138, a selective 5-LOX inhibitor, 1 micro M BAY-X-1005, a FLAP inhibitor, or 100 micro M licofelone, a dual COX/5-LOX inhibitor, did not affect antiadhesive properties of aspirin. (4) Exposure to celecoxib (100 micro M) or rofecoxib (10 micro M) completely suppressed ATL formation caused by aspirin without affecting LTB(4) levels. ZD2138, licofelone and BAY-X-1005 inhibited ATL formation as well as LTB(4) generation. (5) Treatment with LXA(4) reduced PMN adhesion to HUVEC and counteracted the proadhesive effect of celecoxib. In contrast, exposure to Boc-1, an LXA(4) antagonist, counteracts the antiadhesive activities of aspirin. Exposure to U75302, an LTB(4) receptor antagonist, enhances the antiadesive effect of aspirin. (6) Reversal of antiadhesive activities of aspirin by celecoxib was associated with increased expression of LFA-1 on PMN and E-selectin on HUVEC. Addition of LXA(4), ZD2138 and U75302 inhibited these changes. (7) The present results support the notion that inhibition of ATL formation is mechanistically linked to the reversal of the antiadhesive activity of aspirin caused by selective COX-1 inhibitors and suggests that the LTB(4)/ATL balance modulates pro- and antiadhesive activity of nonsteroidal anti-inflammatory drugs at the leukocyte-endothelial cell interface.
(1)与其他抑制环氧化酶(COX)依赖性类花生酸形成的非甾体抗炎药不同,阿司匹林对COX-2的乙酰化作用将类花生酸生物合成从前列腺素E2(PGE2)转变为15-表-脂氧素A4(15-epi-LXA4或阿司匹林触发的脂氧素,ATL)。活化白细胞(PMN)形成ATL需要5-脂氧合酶(5-LOX)的参与,该酶也参与白三烯B4(LTB4)的形成。(2)在本研究中,我们检测了乙酰化COX-2和5-LOX在调节阿司匹林对PMN与内毒素(LPS)预刺激的人脐静脉内皮细胞(HUVEC)黏附的抗黏附作用中的作用。(3)用阿司匹林处理PMN/HUVEC共培养物导致LPS诱导的细胞间黏附呈浓度依赖性抑制。用选择性COX-2抑制剂塞来昔布和罗非昔布处理HUVEC导致阿司匹林的抗黏附作用约70%逆转。相比之下,用1 μM ZD2138(一种选择性5-LOX抑制剂)、1 μM BAY-X-1005(一种FLAP抑制剂)或100 μM利考昔芬(一种双重COX/5-LOX抑制剂)抑制中性粒细胞的5-LOX途径并不影响阿司匹林的抗黏附特性。(4)暴露于塞来昔布(100 μM)或罗非昔布(10 μM)可完全抑制阿司匹林引起的ATL形成,而不影响LTB4水平。ZD2138、利考昔芬和BAY-X-1005抑制ATL形成以及LTB4生成。(5)用LXA4处理可降低PMN与HUVEC的黏附,并抵消塞来昔布的促黏附作用。相比之下,暴露于LXA4拮抗剂Boc-1可抵消阿司匹林的抗黏附活性。暴露于LTB4受体拮抗剂U75302可增强阿司匹林的抗黏附作用。(6)塞来昔布使阿司匹林的抗黏附活性逆转与PMN上LFA-1和HUVEC上E-选择素表达增加有关。添加LXA4、ZD2138和U75302可抑制这些变化。(7)本研究结果支持以下观点:抑制ATL形成在机制上与选择性COX-1抑制剂引起的阿司匹林抗黏附活性逆转相关,并表明LTB4/ATL平衡在白细胞-内皮细胞界面调节非甾体抗炎药的促黏附和抗黏附活性。